Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis.

Jaiswal D, Uzans D, Hayden J, Kiberd BA, Tennankore KK.

Can J Kidney Health Dis. 2016 Dec 13;3:2054358116675345. doi: 10.1177/2054358116675345. eCollection 2016.

2.

Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.

Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y.

J Am Soc Nephrol. 2005 Dec;16(12):3742-7. Epub 2005 Oct 26.

3.

Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.

Nakao K, Mochizuki H.

Drugs Today (Barc). 2009 May;45(5):323-9. doi: 10.1358/dot.2009.45.5.1362067. Review.

PMID:
19584962
4.

Nalfurafine hydrochloride to treat pruritus: a review.

Inui S.

Clin Cosmet Investig Dermatol. 2015 May 11;8:249-55. doi: 10.2147/CCID.S55942. eCollection 2015. Review.

5.

Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.

Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T.

J Am Soc Nephrol. 2000 Mar;11(3):514-9.

6.

Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review.

Lau T, Leung S, Lau W.

Can J Kidney Health Dis. 2016 Mar 28;3:14. doi: 10.1186/s40697-016-0107-8. eCollection 2016. Review.

7.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.

Mathur VS, Kumar J, Crawford PW, Hait H, Sciascia T; TR02 Study Investigators.

Am J Nephrol. 2017;46(6):450-458. doi: 10.1159/000484573. Epub 2017 Dec 18.

PMID:
29253847
8.

Uremic pruritus in chronic hemodialysis patients.

Narita I, Iguchi S, Omori K, Gejyo F.

J Nephrol. 2008 Mar-Apr;21(2):161-5. Review.

PMID:
18446709
9.

Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.

Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H.

Nephrol Dial Transplant. 2010 Apr;25(4):1251-7. doi: 10.1093/ndt/gfp588. Epub 2009 Nov 19.

PMID:
19926718
10.

Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial.

Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, Nakamoto H.

Hepatol Res. 2017 Sep;47(10):972-982. doi: 10.1111/hepr.12830. Epub 2016 Nov 24.

PMID:
27753159
11.

Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus.

Kozono H, Yoshitani H, Nakano R.

Int J Nephrol Renovasc Dis. 2018 Jan 15;11:9-24. doi: 10.2147/IJNRD.S145720. eCollection 2018.

12.

Gabapentin for uremic pruritus: a systematic review of randomized controlled trials.

Eusebio-Alpapara KMV, Castillo RL, Dofitas BL.

Int J Dermatol. 2019 Nov 28. doi: 10.1111/ijd.14708. [Epub ahead of print] Review.

PMID:
31777066
13.

Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG).

J Gastroenterol. 2018 Oct;53(10):1151-1158. doi: 10.1007/s00535-018-1465-z. Epub 2018 Apr 16.

PMID:
29663077
14.

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Jan;48(1):45-50. doi: 10.1111/hepr.12894. Epub 2017 Apr 19.

PMID:
28322485
15.

Is immediate imaging important in managing low back pain?

Andersen JC.

J Athl Train. 2011 Jan-Feb;46(1):99-102. doi: 10.4085/1062-6050-46.1.99.

16.

Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.

Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, Kurihara M, Yanagita T, Suzuki H.

Am J Nephrol. 2012;36(2):175-83. doi: 10.1159/000341268. Epub 2012 Aug 3.

17.

Treatment of pruritus with topically applied opiate receptor antagonist.

Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S, Bigliardi-Qi M.

J Am Acad Dermatol. 2007 Jun;56(6):979-88. Epub 2007 Feb 22.

PMID:
17320241
18.

Therapeutic Effects of Omega-3 Fatty Acids on Chronic Kidney Disease-Associated Pruritus: a Literature Review.

Panahi Y, Dashti-Khavidaki S, Farnood F, Noshad H, Lotfi M, Gharekhani A.

Adv Pharm Bull. 2016 Dec;6(4):509-514. doi: 10.15171/apb.2016.064. Epub 2016 Dec 22. Review.

19.

A Comparison of Uremic Pruritus in Patients Receiving Peritoneal Dialysis and Hemodialysis.

Wu HY, Peng YS, Chen HY, Tsai WC, Yang JY, Hsu SP, Pai MF, Lu HM, Chiang JF, Ko MJ, Wen SY, Chiu HC.

Medicine (Baltimore). 2016 Mar;95(9):e2935. doi: 10.1097/MD.0000000000002935.

20.

Nalfurafine hydrochloride for the treatment of pruritus.

Inui S.

Expert Opin Pharmacother. 2012 Jul;13(10):1507-13. doi: 10.1517/14656566.2012.693164. Epub 2012 Jun 5. Review.

PMID:
22663138

Supplemental Content

Support Center